Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
• Collaborator: Amgen
• Treatments: Antibodies, Monoclonal; Capecitabine; Epirubicin; Oxaliplatin; Panitumumab

Criteria

Inclusion Criteria:

• Untreated, histologically confirmed, KRAS wild type, resectable gastric or esophageal adenocarcinoma

• T2-4 NX M0 disease

• ECOG performance status 0-1

• adequate hematological status

• adequate renal function

• adequate hepatic function

• adequate metabolic function

Exclusion Criteria:

• pregnant or breast feeding women

• previous malignancy other than gastric cancer in the last 5 years except curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix

• arterial or venous thromboembolism within 6 months before enrollment

• clinically significant cardiovascular disease within 1 year before enrollment

• history of interstitial lung disease